(Q37770251)

22 August 2017

1 reference

title

The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update (English)

1 reference

22 August 2017

1 reference

3

Sara De Martin

1 reference

22 August 2017

Pietro Palatini

1

1 reference

PubMed ID

20604736

22 August 2017

Rocco Orlando

series ordinal

2

1 reference

PubMed ID

20604736

22 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

10

1 reference

22 August 2017

1215-1230

1 reference

Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Cytochrome P450 enzyme polymorphisms and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Important drug-drug interactions in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Cardiotoxicity of new antihistamines and cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Changes in plasma protein binding have little clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Enzyme inhibition and induction in liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Drug elimination in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Dose adjustment in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Hepatic cytochrome P450 regulation in disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Clinical pharmacokinetics in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Commentary: a physiological approach to hepatic drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

What is the true clinical significance of plasma protein binding displacement interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Pharmacogenetics of cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Theophylline disposition in patients with hepatic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Metabolism and elimination of quinine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

The plasma protein binding of basic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503704

10.1517/17425255.2010.503704

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20604736